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Consistency of Hemoglobin A1c Testing and Cardiovascular
Outcomes in Medicare Patients With Diabetes
Philip P. Goodney, MD, MS; Karina A. Newhall, MD; Kimon Bekelis, MD; Daniel Gottlieb, MD; Richard Comi, MD; Sushela Chaudrain, MD;
Adrienne E. Faerber, PhD; Todd A. Mackenzie, PhD; Jonathan S. Skinner, PhD
Background-—Annual hemoglobin A1c testing is recommended for patients with diabetes mellitus. However, it is unknown how
consistently patients with diabetes mellitus receive hemoglobin A1c testing over time, or whether testing consistency is associated
with adverse cardiovascular outcomes.
Methods and Results-—We identified 1 574 415 Medicare patients (2002–2012) with diabetes mellitus over the age of 65. We
followed each patient for a minimum of 3 years to determine their consistency in hemoglobin A1C testing, using 3 categories: low
(testing in 0 or 1 of 3 years), medium (testing in 2 of 3 years), and high (testing in all 3 years). In unweighted and inverse
propensity-weighted cohorts, we examined associations between testing consistency and major adverse cardiovascular events,
defined as death, myocardial infarction, stroke, amputation, or the need for leg revascularization. Overall, 70.2% of patients
received high-consistency testing, 17.6% of patients received medium-consistency testing, and 12.2% of patients received low-
consistency testing. When compared to high-consistency testing, low-consistency testing was associated with a higher risk of
adverse cardiovascular events or death in unweighted analyses (hazard ratio [HR]=1.21; 95% CI, 1.20–1.23; P<0.001), inverse
propensity-weighted analyses (HR=1.16; 95% CI, 1.15–1.17; P<0.001), and weighted analyses limited to patients who had at least
4 physician visits annually (HR=1.15; 95% CI, 1.15–1.16; P<0.001). Less-consistent testing was associated with worse results for
each cardiovascular outcome and in analyses using all years as the exposure.
Conclusions-—Consistent annual hemoglobin A1c testing is associated with fewer adverse cardiovascular outcomes in this
observational cohort of Medicare patients of diabetes mellitus. ( J Am Heart Assoc. 2016;5:e003566 doi: 10.1161/
JAHA.116.003566)
Key Words: cardiovascular outcomes • diabetes mellitus • health disparities • health outcomes • hemoglobin A1c
T he Diabetes Control and Complications Trial demon-strated that lower hemoglobin A1C levels were associ-
ated with fewer cardiovascular complications, especially
microvascular complications, in patients with diabetes melli-
tus.1 Based on this study and others,2–6 the American
Diabetes Association,7,8 the National Quality Forum,9 and the
National Committee for Quality Assurance10 all broadly
endorse frequent hemoglobin A1c testing as an important
tool in monitoring diabetic care. Each of these organizations
recommend testing at least once a year, and many endorse
testing at even closer intervals. Because of these recommen-
dations, annual hemoglobin A1c testing rates are commonly
used as a measure of provider and health-system quality of
care for patients with diabetes mellitus.11–14
However, few have examined how consistently a patient
receives hemoglobin A1c testing over a period longer than a
single year. The consistency of hemoglobin A1c testing, which
we define as the proportion of years in which a patient with
diabetes mellitus receives at least 1 hemoglobin A1c test, has
not been well characterized in large cohorts in the United
States.15 Furthermore, though a modest relationship has been
observed between annual hemoglobin A1c testing use and
cardiovascular outcomes,2,4–6,16 the longitudinal relationship
between consistency of hemoglobin A1c testing and cardio-
vascular outcomes, such as myocardial infarction, stroke, and
amputation, has not been established in real-world practice.
To examine the consistency of hemoglobin A1c testing
for patients with diabetes mellitus, we created a large
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national cohort of Medicare patients with diabetes mellitus
and followed each patient for a minimum of 3 years to
determine the consistency with which they received
hemoglobin A1c testing. We then examined associations
between testing consistency and cardiovascular outcomes in
subsequent years, using unweighted and inverse propensity-
weighted analyses, as well as analyses targeting patients
observed at least 4 times per year, to allow adequate
opportunities for physicians to order hemoglobin A1c
testing.
Methods
Creating a Cohort of Medicare Patients With
Diabetes Mellitus
We used the Medicare Physician and Supplier file as well as
the Medicare Denominator file, in the years 2002–2009, to
identify all patients with diagnosis codes indicative of the
presence of diabetes mellitus during that time period. Each
patient was followed forward in time for a minimum of 3
calendar years, through the year 2012. Patients were required
to have a diagnosis codes for diabetes mellitus in 2 of 3
consecutive years for inclusion in the cohort. We used the
year in which the patient entered our cohort to establish the
patient’s comorbidities using the Charlson score. Because
having diabetes mellitus was a requirement for cohort
inclusion, we did not include diabetes mellitus with or without
end organ damage within the overall Charlson score calcu-
lation.17
We excluded patients less than 65 years of age, greater
than 99 years of age, and those not enrolled in fee-for-service
Medicare plans. Further information was obtained using the
denominator file, which contains information about Medicare
and Medicaid eligibility, age, sex, race, and disability. We
recorded patient ZIP code and the hospital referral region of
residence, as described by the Dartmouth Atlas of Health
Care.18 We also linked zip code to the American Community
Survey (2006–2010 aggregation) to identify local area median
income and poverty status. We used county-level data from
countyhealthrankings.org to obtain measures of area level
health: healthy days, smoking, and obesity as described in
previous work.19 Patients left the cohort when they died or
ceased enrollment in Medicare’s Part A or Part B programs,
such as in those who joined a Medicare HMO program such
as Medicare Advantage.
Measuring Consistency in Hemoglobin A1c
Testing
Hemoglobin A1c testing is recommended at least annually for
patients with diabetes mellitus.20 Within our cohort, we
examined whether or not patients had ever undergone
hemoglobin A1c testing. We used the CPT codes available
for this laboratory test (Data S1). This variable has been used
in previous studies using administrative datasets.20–22
To determine our exposure variable, consistency in
hemoglobin A1c testing, we examined how consistently
hemoglobin A1c testing was performed for each patient
during the first 3 years they were followed in our cohort.
Testing consistency was categorized as low (testing in none or
1 year of the first 3 years), medium (testing in any 2 years of
the first 3 years), and high (testing in all 3 of the first 3 years).
Our analysis considered only patients who had at least 1
physician visit per year during the first 3 years, given that a
physician visit would allow for an opportunity for patients to
receive hemoglobin A1C testing. Sensitivity analyses where
none or 1 test during the first 3 years were analyzed
independently were performed, and our findings were similar
to those presented herein.
We excluded any patients who died within the first
3 years. Sensitivity analysis were performed, which required
a minimum of 4 physician visits per year during the first
3 years. We also performed analyses that considered testing
consistency during the entire time each patients appeared
in fee-for-service Medicare, rather than using the first
3 years of testing as an exposure variable and examining
outcomes using survival analysis thereafter. Because find-
ings were similar between these analyses and our outcomes
reported herein, we present only the latter strategy in this
article.
Measuring Cardiovascular Outcomes, by
Consistency Category
After using the first 3 years in the cohort to measure the
exposure variable, we used all remaining years patients
appeared in Medicare claims to measure major adverse
cardiovascular events, beginning on the first day of the fourth
year. We searched for evidence of death, as well as any of the
following cardiovascular events: myocardial infarction, stroke,
amputation, and need for a lower-extremity vascular proce-
dure (codes are shown in Data S1). Death was assessed using
the Denominator file. Myocardial infarction was defined using
International Classification of Diseases, Ninth Revision (ICD-9)
diagnosis codes as in previous reports.23 Stroke was defined
using ICD-9 codes, as published previously. We used a 1-year
look back to exclude patients in whom any of the cardiovas-
cular events occurred in the past year.23,24 We recorded the
occurrence of a major lower-extremity amputation at the
patient level, using current procedural terminology codes
indicative of above- or below-knee amputation. We excluded
toe and forefoot amputations, and traumatic amputations,
although in sensitivity analyses, our results remained similar
DOI: 10.1161/JAHA.116.003566 Journal of the American Heart Association 2
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when we included toe or forefoot amputations in our analysis.
Leg revascularization procedures were also measured using
diagnosis and procedure codes reported in our previous
work20,25 A composite outcome of a major adverse cardiac
event (MACE) was analyzed as well, defined as the occurrence
of any of the following: death, myocardial infarction, stroke,
major leg amputation, or need for lower-extremity revascu-
larization.
All cardiovascular outcomes were assessed using time-
to-event analyses, with the initial time period beginning on the
first day of the fourth year; the first 3 years in the cohort were
used to assign the exposure. Death was allowed in the fourth
in the cohort and thereafter. Any major adverse cardiovascu-
lar events occurring in the first 3 years were excluded. If
patients left fee-for-service Medicare claims for Medicare
Advantage or other non-fee-for-service programs during this
interval, they were censored on the date they ceased to
appear in the fee-for-service Medicare program.
Statistical Analyses
We began by examining the consistency in hemoglobin A1c
testing among Medicare patients with diabetes mellitus
between 2002 and 2012. We created Cox survival models
to understand associations between the consistency of
testing and cardiovascular outcomes. These models were
adjusted for age, sex, race, Medicaid eligibility, disability
status, and Charlson score as well as regional variables
indicative of health status, income, and poverty.
Crude results were examined using linear analyses before
examining our 3 consistency categories and over time.
Because patient characteristics differed across the categories
of consistency in hemoglobin A1c testing (Table 1), we used
multilevel inverse propensity weighting to develop a matched
cohort of patients, based on the patient’s likelihood to receive
low-, medium-, and high-consistency testing.26,27 We devel-
oped multinomial logistic models that identified patient and
structural factors associated with each category of consis-
tency in hemoglobin A1c testing. We then used the inverse of
these probabilities to weight patients and balance the testing
groups. Models were run using both baseline information only,
as well as allowing covariates, including the year of testing, to
change annually as the patient progressed through each year
in the study. Both efforts produced similar results, and
therefore the baseline-adjusted models are presented herein.
P values are reported across all three categories.
All analyses were performed using SAS (SAS Institute Inc.,
Cary, NC) and STATA software (StataCorp LP, College Station,
TX). The Geisel School of Medicine’s Center for the Protection
of Human Subjects approved our study. Informed consent was
waived as part of the study, because it involved only
secondary data-set analyses.
Results
Patient Characteristics and Unadjusted
Outcomes, by Testing Consistency
Between 2002 and 2009, we identified 1 574 415 individual
Medicare patients with diabetes mellitus. These patients were
followed for a mean of 6.3 years in our cohort, with a range
from 3 to 11 years. Overall, 70.2% of patients received
high-consistency testing, 17.6% of patients received medium-
consistency testing, and 12.2% of patients received low-
consistency testing. Testing consistency in the first 3 years
was reflected in testing in later years. For example, those with
high-consistency testing in the first 3 years had testing in 88%
of later years, and those with low-consistency testing during
the first 3 years had testing in 49% of later years.
Patients were who received low-consistency testing were
older than patients receiving high-consistency testing when
they entered the cohort; the mean age was nearly 2 years
older for those receiving low-consistency testing when
compared to those receiving high-consistency testing (76.3
vs 74.6 years; P<0.001; Table 1). Differences by race were
evident as well, as 14.3% of low-consistency testing patients
were black, whereas 10.0% of high-consistency testing
patients were black (P<0.0001). Finally, a larger proportion
of patients getting low-consistency testing were on disability
when compared to high-consistency testing (15.5% vs 11.9%;
P<0.0001).
Because a patient clinic visit is an opportunity for a
physician to order hemoglobin A1c testing, we examined
patient visit patterns in our cohort. Overall, patients had an
average of 17 physician visits in each year during the study
period. Of these visits, an average of 8 were with a primary
care physician. Patients were seen often by physicians; only
9% of Medicare enrollees in the cohort had fewer than 4
physician visits annually. Differences in the number of visits
were evident across categories of testing consistency
(Table 1). For example, patients who received low-consistency
testing had a higher number of physician visits than those
receiving high-consistency testing (19.7 vs 16.3 visits;
P<0.001), but were also more likely to have fewer than 4
physician visits per year (11.1% vs 8.6%; P<0.001).
Cardiovascular Outcomes, by Testing
Consistency
In unweighted analyses, we found 62.3% of patients treated
with low-consistency testing experienced death or a major
adverse cardiovascular event within 7 years of follow-up
(Figure A). The rate of death or an adverse cardiovascular
event was 13.2% lower, in absolute terms, for patients treated
with high-consistency testing (49.0%), a difference that was
highly significant across testing consistency categories (log
DOI: 10.1161/JAHA.116.003566 Journal of the American Heart Association 3
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rank, P<0.001). Similar trends were observed for all individual
components of our adverse cardiovascular outcomes, includ-
ing death, myocardial infarction, stroke, lower-extremity
vascular procedures, and leg amputation (FigureB througF).
We calculated unweighted hazard ratios, with surrounding
95% CIs, for each outcome, across consistency categories.
These demonstrated an inverse relationship between testing
consistency and the risk of death or a major adverse
cardiovascular event, as well as each of its individual
components (Table 2).
Cardiovascular Outcomes, by Testing
Consistency in Inverse Propensity-Weighted
Analyses
Because of the differences in patient characteristics across
categories of testing consistency, we used inverse propensity
weighting to generate 3 groups, which were similar across
patient characteristics (Table 1). Many of these differences
remained statistically significant given our large sample size,
but all patient demographic characteristics in the inverse
propensity weighted analyses varied by less than 1% across
testing consistency categories.
As with our unweighted findings, Cox proportional hazards
models derived from the inverse propensity-weighted cohort
again demonstrated that low-consistency testing remained
associated with worse cardiovascular outcomes, both in our
composite outcome (MACE) and its individual components
(Table 2). For example, patients receiving low-consistency
testing were 16% more likely to experience a cardiovascular
adverse event than those who had high-consistency testing
(adjusted hazard ratio [HR]=1.16; 95% CI, 1.15–1.17;
P<0.001). These findings were again similar for each of the
components of our composite outcome.
Last, to ensure we accounted for differences in patient visit
type and frequency, we repeated these analyses, but limited
to patients who were seen by physicians at least 4 times per
year to ensure that physicians had several opportunities to
order hemoglobin A1c testing. As with our unweighted and
inverse propensity-weighted analyses, we again found that
low-consistency testing was associated with a higher risk of
death and major adverse cardiovascular events (Table 2), with
little change in the effect size evident in this sensitivity
analysis.
Discussion
Hemoglobin A1c testing has been shown to be an important
tool in guiding the care of patients with diabetes mellitus.
Because of this, hemoglobin A1c testing has been established
as an important quality measure for both physicians and
health care systems. Success toward this effort is evident in
our analysis, given that two thirds of patients received high-
consistency testing. However, for one third of patients with
diabetes mellitus in our analysis, testing did not occur in each
year, and for 1 in 9, testing occurred in fewer than half of the
years. These “missed opportunities” for hemoglobin A1c
testing were associated with significant disparities in cardio-
vascular outcomes. Patients who received the least-consis-
tent testing had the most cardiovascular complications,
including significantly higher rates of myocardial infarction,
stroke, amputation, and death.
These results are undoubtedly subject to the limitations of
observational analyses using administrative data sets,
wherein clinical details, such as the absolute value of the
hemoglobin A1c test and its changes over time, are not
available. However, our findings were remarkably similar and
consistent across multiple endpoints and in several sensitivity
analyses, suggesting that a simple confounding variable is
unlikely to explain these findings directly.
Broad support for annual hemoglobin A1c testing, and for
the use of annual testing as a quality metric, exists in national
society guidelines, physician groups, and quality improvement
organizations. However, our study, as well as others, suggests
that translating these recommendations into practice has met
with varying success. For example, a recent report from the
US National Ambulatory Medical Care Survey suggested that
more than 25% of patients followed for diabetes mellitus have
missed testing opportunities.15 These results are consistent
with our observational findings in this large, national analysis
of diabetic care provided to Medicare patients in the last
decade.
Our results suggest that the consistency of hemoglobin
A1c testing could be an important way to measure of the
quality of care provided to patients with diabetes mellitus.
Despite widespread endorsement and adoption, using annual
hemoglobin A1c testing rates as a quality measure has little, if
any, direct relationship to better cardiovascular outcomes.28
Our work, though observational in nature, suggests that more-
consistent testing over time is associated with better
cardiovascular outcomes.
Is this relationship plausible, especially given that admin-
istrative data sets that allow examination of testing patterns
do not current allow actual measurement of A1c testing
results? A theoretical framework proposing an explanatory
mechanism has been described by Presseau et al.,29 wherein
they hypothesized that highly consistent hemoglobin A1c
testing is a derivative of the consistent patient and physician
interactions that occur in the setting of clinical trials. Our
results are consistent with this view. Whereas Presseau et al.
strike a cautionary note—that raising consistency alone will
not necessarily improve the quality of patient-physician
interactions—testing consistency allows a determination of
DOI: 10.1161/JAHA.116.003566 Journal of the American Heart Association 6
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Freedom From Major Adverse Cardiovascular Event 
(MACE) or Death
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Consistency of TesƟng
High  783512 629628 506388 409302 316961 239241 174619
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Figure. A, Freedom from major adverse cardiac events, by testing consistency category. B, Freedom from death,
by testing consistency category. C, Freedom from myocardial infarction, by testing consistency category. D,
Freedom from stroke, by testing consistency category. E, Freedom from leg vascular procedure, by testing
consistency category. F, Freedom from amputation, by testing consistency category.
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which patients were most commonly engaged with their
health care providers and are thereby likely to achieve
stronger relationships with their health care team over time.
These stronger relationships could potentially manifest in
better outcomes, an increasingly common theme in cardio-
vascular care.30,31
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Figure. Continued
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Quality metrics for providers and health care systems who
care for patients with diabetes mellitus could be designed to
help reach this goal. At present, only annual rates are
reported in most care settings, and the longitudinal nature of
hemoglobin A1C testing is not emphasized.16,32,33 The direct
association between higher-consistency testing and fewer
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Figure. Continued
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deaths, myocardial infarctions, strokes, and amputations—all
outcomes of significant importance to patients—makes this
an important opportunity.
Building longitudinal quality measures for patients with
diabetes mellitus will have obvious challenges. These metrics
will measure engagement from patients as well as providers.
Success would require patient compliance over time, just as
much as physician compliance. These challenges, however,
would also bring opportunities. For example, the clarity offered
to patients frommetrics emphasizing consistent testingmay be
easier to for patients to understand (eg, get your flu shot every
year, a common Centers for Disease Control and Prevention
public health message34) than guidelines emphasizing target-
ing A1c levels, which often are poorly understood by
patients.35,36 This could help patients and physicians achieve
better adherence and health care engagement as they manage
this challenging chronic disease. And finally, though a longitu-
dinal “consistency” metric may be difficult to collect, new
information technology systems will likely make measures of
this nature easier to design and implement in future years.
As mentioned previously, our study has several important
limitations. First, testing the value of testing, especially in a
longitudinal sense, requires not just the evidence that
hemoglobin A1C testing has been performed, but also the
actual testing results. Current efforts to use “enriched”
claims-based data sets that have the actual values, rather
than just the use of testing for just this purpose, will help us
to attain this goal.37 Second, the main “preventive measure”
we studied was hemoglobin A1C testing, which is a valuable
tool for measuring diabetic care, but certainly not the only tool
available for prevention of diabetic complications. Third,
though our study closely examined the cardiovascular com-
plications that occur with diabetes mellitus, we were
prevented by data limitations from analyzing other types of
complications, such as nephropathy and retinopathy. Fourth,
hemoglobin A1c targeted diabetes mellitus management has
shown variable effectiveness in limiting cardiovascular com-
plications in randomized trials38–40 and has shown the most
efficacy in trials of patients with type 1 diabetes mellitus, a
population unlikely to be specifically reflected in our popula-
tion of older Medicare patients.
In summary, though more than two thirds of Medicare
patients with diabetes mellitus receive hemoglobin A1c
testing every year, nearly one third of these patients were
not tested each year. For nearly 1 in 9 diabetic patients,
hemoglobin A1c testing occurred in fewer than half of the
Table 2. Hazard Ratios for Adverse Outcomes, by Hemoglobin A1C Testing Category
Low Consistency
Testing
95% Confidence
Intervals
Medium Consistency
Testing 95% CIs
Unweighted, all patients
Any leg vascular procedure 1.12 1.08 1.15 1.09 1.06 1.11
Myocardial infarction 1.19 1.15 1.22 1.14 1.12 1.17
Death 1.21 1.20 1.23 1.12 1.11 1.13
Amputation 1.31 1.23 1.39 1.12 1.06 1.19
Stroke 1.20 1.16 1.23 1.14 1.11 1.16
Major adverse cardiovascular event 1.21 1.20 1.23 1.13 1.12 1.14
Inverse propensity weighted, all patients
Any leg vascular procedure 1.08 1.07 1.10 1.06 1.05 1.08
Myocardial infarction 1.12 1.11 1.13 1.10 1.09 1.12
Death 1.16 1.15 1.17 1.08 1.08 1.09
Amputation 1.26 1.22 1.30 1.09 1.06 1.13
Stroke 1.16 1.14 1.17 1.11 1.09 1.12
Major adverse cardiovascular event 1.16 1.15 1.17 1.09 1.09 1.10
Inverse propensity weighted, with all patients having at least four physician visits per year
Any leg vascular procedure 1.05 1.04 1.07 1.06 1.05 1.08
Myocardial infarction 1.08 1.06 1.09 1.09 1.08 1.11
Death 1.17 1.16 1.17 1.09 1.08 1.09
Amputation 1.23 1.19 1.27 1.08 1.05 1.12
Stroke 1.13 1.12 1.15 1.09 1.08 1.11
Major adverse cardiovascular event 1.15 1.15 1.16 1.09 1.08 1.10
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years in which we studied their care. Given that differences in
testing consistency are associated with poorer cardiovascular
outcomes, multiyear quality metrics for hemoglobin A1c
testing may help improve cardiovascular care for patients with
diabetes mellitus. Future efforts to limit cardiovascular
complications for patients with diabetes mellitus should
consider quality metrics that incentivize longitudinal
approaches toward ensuring high-quality diabetic care.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
 
  
Data S1: ICD9 and CPT codes used to identify patients with diabetes, as well as major adverse 
cardiovascular outcomes in our analysis. 
 
 
   
Diabetes Diagnosis Codes: 
249.xx Secondary diabetes mellitus 
250.xx Diabetes mellitus 
   
Myocardial Infarction Diagnosis Codes: 
410.xx: Acute myocardial infarction 
411.xx: Other acute and subacute forms of ischemic heart disease 
412.xx: Old myocardial infarction 
413.xx: Angina pectoris 
414.xx: Other forms of chronic ischemic heart disease 
   
Stroke Diagnosis Codes: 
433.00 to 433.91: occlusion/stenosis, precerebral artery 
342 or 438: history of previous stroke 
435 or 781.4:  transient ischemic attack 
362.34 or 368.12:  amaurosis fugax 
997.0, 997.00, 997.01, and 997.09: In-hopsital stroke. 
   
Amputation Procedure Codes 
27590 AMPUTATION THIGH THROUGH FEMUR ANY 
LEVEL 
27591 AMP THI THRU FEMUR LVL IMMT FITG TQ 
W/1ST CST 
27592 AMPUTATION THIGH THRU FEMUR OPEN 
CIRCULAR 
27880 AMPUTATION LEG THROUGH TIBIA&FIBULA 
27881 AMP LEG THRU TIBFIB W/IMMT FITG TQ 
W/1ST CST 
27882 AMPUTATION LEG THRU TIBIA&FIBULA OPEN 
CIRCULAR 
   
Leg Vascular Procedure Codes  
36200 INTRODUCTION CATHETER AORTA 
36245 SLCTV CATHJ EA 1ST ORD ABDL PEL/LXTR ART 
BRNCH 
36246 SLCTV CATHJ 2ND ORDER ABDL PEL/LXTR ART 
BRNCH 
36247 SLCTV CATHJ 3RD+ ORD SLCTV ABDL PEL/LXTR 
BRNCH 
36248 SLCTV CATHJ EA 2ND+ ORD ABDL PEL/LXTR 
ART BRNCH 
0238T TRLUML PERIPHERAL ATHERECTOMY ILIAC 
ARTERY EA 
35452 TRLUML BALLOON ANGIOPLASTY OPEN 
AORTIC 
35454 TRLUML BALO ANGIOP OPN ILIAC 
35456 TRLUML BALO ANGIOP OPN FEM-POP 
35459 TRLUML BALO ANGIOP OPN TIBIOPRONEAL 
TRNK&BRNCH 
35470 TRLUML BALO ANGIOP PRQ TIBPRNL 
TRNK/BRNCH EA 
35472 TRLUML BALLOON ANGIOPLASTY 
PERCUTANEOUS AORTIC 
35473 TRLUML BALO ANGIOP PRQ ILIAC 
35474 TRLUML BALO ANGIOP PRQ FEMPOP 
35481 TRLUML PRPH ATHRC OPN AORTIC 
35482 TRLUML PRPH ATHRC OPN ILIAC 
35483 TRLUML PRPH ATHRC OPN FEMPOP 
35485 TRLUML PRPH ATHRC OPN TIBPRNL 
TRNK&BRNCH 
35491 TRLUML PRPH ATHRC PRQ AORTIC 
35492 TRLUML PRPH ATHRC PRQ ILIAC 
35493 TRLUML PRPH ATHRC PRQ FEMPOP 
35495 TRLUML PRPH ATHRC PRQ TIBPRNL 
TRNK&BRNCH 
37205 TCAT PLMT IV STENT PERCUTANEOUS 1ST 
VESSEL 
37206 TCAT PLMT IV STENT PERCUTANEOUS EACH 
ADDL VESSEL 
37207 TCAT PLMT IV STENT OPEN 1ST VESSEL 
37208 TCAT PLMT IV STENT OPEN EACH ADDL VESSEL 
37220 REVASCULARIZATION ILIAC ARTERY ANGIOP 
1ST VSL 
37221 REVSC OPN/PRQ ILIAC ART W/STNT PLMT & 
ANGIOPLSTY 
37222 REVASCULARIZATION ILIAC ART ANGIOP EA 
IPSI VSL 
37223 REVSC OPN/PRQ ILIAC ART W/STNT & ANGIOP 
IPSILATL 
37224 REVSC OPN/PRG FEM/POP W/ANGIOPLASTY 
UNI 
37225 REVSC OPN/PRQ FEM/POP W/ATHRC/ANGIOP 
SM VSL 
37226 REVSC OPN/PRQ FEM/POP W/STNT/ANGIOP 
SM VSL 
37227 REVSC OPN/PRQ FEM/POP 
W/STNT/ATHRC/ANGIOP SM VSL 
37228 REVSC OPN/PRQ TIB/PERO W/ANGIOPLASTY 
UNI 
37229 REVSC OPN/PRQ TIB/PERO W/ATHRC/ANGIOP 
SM VSL 
37230 REVSC OPN/PRQ TIB/PERO W/STNT/ANGIOP 
SM VSL 
37231 REVSC OPN/PRQ TIB/PERO 
W/STNT/ATHR/ANGIOP SM VSL 
37232 REVSC OPN/PRQ TIB/PERO W/ANGIOPLASTY 
UNI EA VSL 
37233 REVSC OPN/PRQ TIB/PERO W/ATHRC/ANGIOP 
UNI EA VSL 
37234 REVSC OPN/PRQ TIB/PERO W/STNT/ANGIOP 
UNI EA VSL 
37235 REVSC OPN/PRQ TIB/PERO 
W/STNT/ATHR/ANGIOP EA VSL 
35302 TEAEC W/GRAFT SUPERFICIAL FEMORAL 
ARTERY 
35303 TEAEC W/GRAFT POPLITEAL ARTERY 
35304 TEAEC W/GRAFT TIBIOPERONEAL TRUNK 
ARTERY 
35305 TEAEC W/GRAFT TIBIAL/PERONEAL ART 1ST 
VESSEL 
35306 TEAEC W/GRAFT EA ADDL TIBIAL/PERONEAL 
ART 
35351 TEAEC W/WO PATCH GRAFT ILIAC 
35355 TEAEC W/WO PATCH GRAFT ILIOFEMORAL 
35361 TEAEC W/WO PATCH GRAFT COMBINED 
AORTOILIAC 
35363 TEAEC W/WO PATCH GRAFT COMBINED 
AORTOILIOFEMORAL 
35371 TEAEC W/WO PATCH GRAFT COMMON 
FEMORAL 
35372 TEAEC W/WO PATCH GRAFT DEEP PROFUNDA 
FEMORAL 
35521 BYPASS W/VEIN AXILLARY-FEMORAL 
35533 BYPASS W/VEIN AXILLARY-FEMORAL-
FEMORAL 
35538 BYPASS W/VEIN AORTOBI-ILIAC 
35539 BYPASS W/VEIN AORTOFEMORAL 
35540 BYPASS W/VEIN AORTOBIFEMORAL 
35541 BYP W/VEIN AORTOILIAC/BI-ILIAC 
35546 BYP W/VEIN AORTOFEM/BIFEM 
35548 BYP W/VEIN AORTOILIOFEM UNI 
35549 BYP W/VEIN AORTOILIOFEM BI 
35551 BYP W/VEIN AORTOFEMPOP 
35556 BYPASS W/VEIN FEMORAL-POPLITEAL 
35558 BYPASS W/VEIN FEMORAL-FEMORAL 
35563 BYPASS W/VEIN ILIOILIAC 
35565 BYPASS W/VEIN ILIOFEMORAL 
35566 BYP FEM-ANT TIBL PST TIBL PRONEAL 
ART/OTH DSTL 
35571 BYP W/VEIN POP-TIBL-PRONEAL ART/OTH 
DSTL VSL 
35583 IN-SITU VEIN BYPASS FEMORAL-POPLITEAL 
35585 IN-SITU FEM-ANT TIBL PST TIBL/PRONEAL ART 
35587 IN-SITU VEIN BYP POP-TIBL PRONEAL 
35621 BYP OTH/THN VEIN AXILLARY-FEMORAL 
35623 BYP OTH/THN VEIN AXILLARY-POPLITEAL/-
TIBIAL 
35637 BYP OTH/THN VEIN AORTOILIAC 
35638 BYP OTH/THN VEIN AORTOBI-ILIAC 
35646 BYP OTH/THN VEIN AORTOBIFEMORAL 
35647 BYP OTH/THN VEIN AORTOFEMORAL 
35651 BYP OTH/THN VEIN AORTOFEMPOP 
35654 BYP OTH/THN VEIN AXILLARY-FEMORAL-
FEMORAL 
35656 BYP OTH/THN VEIN FEMORAL-POPLITEAL 
35661 BYP OTH/THN VEIN FEMORAL-FEMORAL 
35663 BYP OTH/THN VEIN ILIOILIAC 
35665 BYP OTH/THN VEIN ILIOFEMORAL 
35666 BYP OTH/THN VEIN FEM-ANT TIBL PST 
TIBL/PRONEAL 
35671 BYP OTH/THN VEIN POPLITEAL-TIBIAL/-
PERONEAL ART 
35681 BYPASS COMPOSITE GRAFT PROSTHETIC & 
VEIN 
35682 BYP AUTOG COMPOSIT 2 SEG VEINS FROM 2 
LOCATIONS 
35683 BYP AUTOG COMPOSIT 3/> SEG FROM 2/> 
LOCATION 
35879 REVJ LXTR ARTL BYP OPN VEIN PATCH ANGIOP 
35881 REVJ LXTR ARTL BYP OPN W/SGMTL VEIN 
INTERPOS 
35883 REVISION FEMORAL ANAST OPEN NONAUTOG 
GRAFT 
35884 REVISION FEMORAL ANAST OPEN W/AUTOG 
GRAFT 
